5,6,7,8-四氢中氮茚-1-羧酸 | 61009-82-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 5,6,7,8-四氢中氮茚-1-羧酸
• 英文名称: 5,6,7,8-tetrahydroindolizine-1-carboxylic acid
• 英文别名: 5,6,7,8-tetrahydro-indolizine-1-carboxylic acid；5,6,7,8-Tetrahydroindolizin-1-carbonsaeure
• CAS: 61009-82-3
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: RAVWRTMGLMSMGT-UHFFFAOYSA-N

物化性质

• 熔点：
  151-153 °C (decomp)
• 沸点：
  351.9±30.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,6,7,8-四氢中氮茚-1-羧酸 生成 氮茚,5,6,7,8-四氢-(6CI,7CI,9CI)
  参考文献：
  名称：

  PIZZORNO M. T.; ALBONICO S. M., J. ORG. CHEM. , 1977, 42, NO 5, 909-910

  摘要：

  DOI：
• 作为产物：
  描述：

  5,6,7,8-四氢吲哚嗪-1-羧酸甲酯 在 水 、 lithium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 生成 5,6,7,8-四氢中氮茚-1-羧酸
  参考文献：
  名称：

  [EN] NEW ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  [FR] NOUVEAUX COMPOSÉS ISOINDOLINE OU ISOQUINOLÉINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

  摘要：

  式(I)的化合物：其中Het、R3、R4、R5、R7、R8、R9、T、p、p'、q和q'的定义如描述中所定义，是在治疗癌症以及自身免疫和免疫系统疾病中有用的促凋亡剂。

  公开号：

  WO2015011164A1

文献信息

• IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS
  申请人：BIOGEN MA INC.

  公开号：US20220089592A1

  公开（公告）日：2022-03-24

  This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

  这项发明涉及Imidazo[1,2-a]pyridinyl Derivatives的化合物（I′）或其药学上可接受的盐，其中所有变量如规范中所定义，能够调节IRAK4的活性。该发明进一步提供了一种制造该发明化合物的方法，以及它们在治疗中的方法。该发明还提供了它们的制备方法，医学用途，特别是在治疗和管理炎症性疾病、自身免疫疾病、癌症、心血管疾病、中枢神经系统疾病、皮肤疾病、眼科疾病和骨骼疾病等疾病或疾病的用途。
• [EN] FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PYRROLEDICARBOXAMIDES FUSIONNÉS ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2013113860A1

  公开（公告）日：2013-08-08

  The present invention relates to fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in the claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

  本发明涉及公式（I）中的融合吡咯二羧酰胺，其中R1至R9、X、m和n如权利要求中所定义。公式（I）化合物是酸敏感钾通道TASK-1的抑制剂，适用于治疗TASK-1通道介导的疾病，如心律失常，特别是心房心律失常，如心房颤动或心房扑动，以及呼吸系统疾病，特别是与睡眠相关的呼吸系统疾病，如睡眠呼吸暂停症等。
• Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals
  申请人：SANOFI

  公开号：US20150018342A1

  公开（公告）日：2015-01-15

  The present invention relates to fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in the claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

  本发明涉及式(I)的融合吡咯二甲酰胺，其中R1至R9、X、m和n如权利要求所定义。式(I)化合物是酸敏感钾通道TASK-1的抑制剂，适用于治疗TASK-1通道介导的疾病，如心律失常，特别是心房心律失常，如心房颤动或心房扑动，以及呼吸障碍，特别是睡眠相关呼吸障碍，如睡眠呼吸暂停等。
• Fused pyrroledicarboxamides and their use as pharmaceuticals
  申请人：SANOFI

  公开号：US09284333B2

  公开（公告）日：2016-03-15

  The present invention relates to fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in the claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

  本发明涉及式(I)的熔合吡咯二羧酰胺化合物，其中R1到R9，X，m和n如权利要求所述。式(I)化合物是酸敏感钾通道TASK-1的抑制剂，适用于治疗TASK-1通道介导的疾病，如心律失常，特别是房颤或房扑，以及呼吸系统疾病，特别是与睡眠有关的呼吸系统疾病，如睡眠呼吸暂停等。
• ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20160194304A1

  公开（公告）日：2016-07-07

  Compounds of formula (I): wherein Het, R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , T, p, p′, q, and q′ are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式(I)的化合物：其中，Het、R3、R4、R5、R7、R8、R9、T、p、p'、q和q'的定义如说明书所述。包含这些化合物的药物制剂在治疗涉及凋亡缺陷的病理学方面有用，例如癌症、自身免疫性疾病和免疫系统疾病。